Objective:To analyze the effects of centralized volume-based procurement policy for coronary stents on direct medical expenses related to cardiovascular disease within one year after first Percutaneous Coronary Intervention(PCI)among patients with Acute Coronary Syndrome(ACS),based on real-world data of Shanghai medical institutions.Methods:ACS patients who underwent their first PCI in Shanghai between March 2019 and April 2022 were selected,and their data of cardiovascular-related medical care and direct medical expenses in outpatient visits and readmissions within one year after first PCI were collected.The policy effects on direct medical expenses related to cardiovascular disease within 1 month,3 months,6 months and 1 year after first PCI were analyzed,using Wilcoxon rank sum tests and a multilevel generalized linear mixed model.Results:After the implementation of coronary stent policy,the average total direct medical expense(including outpatient visits and readmissions)related to cardiovascular disease within 1 month,3 months,6 months and 1 year after first PCI in ACS patients significantly decreased in Shanghai;and the multivariate generalized linear mixed model also indicated that the policy implementation reduced the direct medical expenses related to cardiovascular disease for these patients within one year after first PCI.Conclusions:The implementation of coronary stent policy in Shanghai reduced direct medical expenses related to cardiovascular disease within one year after first PCI in ACS patients,alleviating patients' financial burden.It is recommended that medical expenses after first PCI among patients with ACS should be further reduced and that long-term follow-up assessment on social impacts of coronary stent policies should be conducted.

Objective:To analyze the effects of centralized volume-based procurement policy for coronary stents on direct medical expenses related to cardiovascular disease within one year after first Percutaneous Coronary Intervention(PCI)among patients with Acute Coronary Syndrome(ACS),based on real-world data of Shanghai medical institutions.Methods:ACS patients who underwent their first PCI in Shanghai between March 2019 and April 2022 were selected,and their data of cardiovascular-related medical care and direct medical expenses in outpatient visits and readmissions within one year after first PCI were collected.The policy effects on direct medical expenses related to cardiovascular disease within 1 month,3 months,6 months and 1 year after first PCI were analyzed,using Wilcoxon rank sum tests and a multilevel generalized linear mixed model.Results:After the implementation of coronary stent policy,the average total direct medical expense(including outpatient visits and readmissions)related to cardiovascular disease within 1 month,3 months,6 months and 1 year after first PCI in ACS patients significantly decreased in Shanghai;and the multivariate generalized linear mixed model also indicated that the policy implementation reduced the direct medical expenses related to cardiovascular disease for these patients within one year after first PCI.Conclusions:The implementation of coronary stent policy in Shanghai reduced direct medical expenses related to cardiovascular disease within one year after first PCI in ACS patients,alleviating patients' financial burden.It is recommended that medical expenses after first PCI among patients with ACS should be further reduced and that long-term follow-up assessment on social impacts of coronary stent policies should be conducted.

Objective A 2-PSU/ RR parallel ankle rehabilitation robot was designed, and the biomechanical properties of human muscles were also analyzed, so as to study rehabilitation strategy of the ankle rehabilitation robot. Methods The actual workspace of the robot was obtained by numerical discrete search method, and the effect of structural parameter changes on the height of robot moving platform was explored. Then the human biomechanical responses such as muscle force and muscle mobility were obtained by human biomechanical simulation software AnyBody, so as to investigate the effect of moving platform height changes on muscle behavior. Results The robot could meet the demand of ankle plantarflexion/ dorsiflexion and inversion/ eversion motion. Appropriately increasing the initial inclination angle and decreasing the length of the fixed-length bar enabled the ankle rehabilitation robot to have a lower overall height. The height of the moving platform was decreased by 10 mm in turn, and the muscle force and muscle activity of the human body involved in the movement were decreased to a certain extent. Conclusions This study provides a new design solution for ankle rehabilitation, offers theoretical guidance for motion analysis of the ankle rehabilitation robot, and accelerates rehabilitation of the patients’ ankles by modifying the mechanism parameters.

Objective:To investigate the application value of aortic dissection detection risk score (ADD-RS) combined with D-dimer (DD) in the early diagnosis of acute aortic dissection (AAD).Methods:The clinical data of 70 patients with suspected aortic dissection detection admitted to The Second Hospital of Jiaxing from August 2019 to April 2020 were collected. All patients were scored using the ADD-RS, and grouped according to the scoring results. The sensitivity and specificity of ADD-RS plus DD in the early diagnosis of AAD were calculated. The areas under the receiver operating characteristic (ROC) curves that were plotted for drADD-RS plus DD versus DD alone to screen AAD were compared to evaluate efficacy. Results:CT angiography results showed that among 70 patients with suspected AAD, 29 patients had AAD and 41 patients had no AAD. A total of 21 patients were scored 0, 41 patients were scored > 1, and 8 patients were scored > 0. ADD-RS > 0 had an overall sensitivity of 79.31% and a specificity of 36.59% for AAD diagnosis. DD test results had an overall sensitivity of 86.20% and a specificity of 36.50% for AAD diagnosis. The area under the ROC curve of ADD-RS = 0 plus DD-negative result and the area under the ROC curve of DD-negative result alone in ruling out AAD were 0.885 with 95% CI (0.786-0.949) and 0.787 with 95% CI (0.673-0.876), respectively. The difference between the two groups was statistically significant ( P = 0.024). Conclusion:Compared with DD-negative result alone, the ADD-RS = 0 plus DD-negative result strategy offers greater specificity to rule out AAD. The combined strategy has a greater efficacy in ruling out AAD. However, a multi-center study involving a large sample is required for in-depth evaluation.

In the paper， national and international ethical requirements and supervision on stem cell research and clinical application were analyzed after literature review. It is suggested that the development of stem cell technology should be timely tracked， prospective ethical research related to stem cells should be enhanced， and that stem cell research and clinical translation should comply with relevant international ethical guidelines and national regulations in China. In addition， it is indicated that the oversight of stem cell products and their clinical use will be continuously improved in our country.

ObjectiveTo analyze the effectiveness and safety of clinical use of different types of stem cells to provide evidence for governmental supervision of key issues in clinical utilization of stem cells. MethodsSix literature databases in China and abroad were searched for relevant literature published from January 2010 to July 2020， and a systematic review was conducted. ResultsThe study showed 72 studies concerning the effectiveness and safety of different types of stem cells in clinical utilization. Although clinical utilization of stem cells had some therapeutic effects for certain diseases， their long-term effect and safety need to be further evaluated， especially their potential risk of tumorigenicity. ConclusionTo protect the patients’ interest， physicians should fully weigh the benefits against the risks of clinical utilization of stem cells， and relevant governmental departments should strengthen supervision of ethics of clinical research and therapies involving stem cells as well as supervision of stem cell products.